179626-26-7

Basic information

• Product Name: ethyl 4-(2-oxopyridin-1(2H)-yl)benzoate
• Synonyms: ethyl 4-(2-oxopyridin-1(2H)-yl)benzoate
• CAS NO: 179626-26-7
• Molecular Formula: C₁₄H₁₃NO₃
• Molecular Weight: 243.25792
• Mol File: 179626-26-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 4-(2-oxopyridin-1(2H)-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-oxopyridin-1(2H)-yl)benzoate(179626-26-7)
• EPA Substance Registry System: ethyl 4-(2-oxopyridin-1(2H)-yl)benzoate(179626-26-7)

Safety Data

• Hazardous Substances Data: 179626-26-7(Hazardous Substances Data)

Upstream product

• 142-08-5 2-Pyridone 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 142-08-5 2-hydroxypyridin 
• 4334-88-7 p-ethoxycarbonylphenylboronic acid 
• 14047-29-1 4-carboxyphenylboronic acid 

Downstream Products

• 766556-54-1 4-(2-oxopyridine-1-(2H)-yl)benzoic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors

Factor Xa (fXa) is a crucial player in various thromboembolic disorders. Inhibition of fXa can provide safe and effective antithrombotic effects. In this study, a series of anthranilamide compounds were designed by utilizing structure-based design strategies. Optimization at P1 and P4 groups led to the discovery of compound 16g: a highly potent, selective fXa inhibitor with pronounced in vitro anticoagulant activity. Moreover, 16g also displayed excellent in vivo antithrombotic activity in the rat venous thrombosis (VT) and arteriovenous shunt (AV-SHUNT) models. The bleeding risk evaluation showed that 16g had a safer profile than that of betrixaban at 1 mg/kg and 5 mg/kg dose. Additionally, 16g also exhibited satisfactory PK profiles. Eventually, 16g was selected to investigate its effect on hypoxia-reoxygenation- induced H9C2 cell viability. MTT results showed that H9C2 cell viability can be remarkably alleviated by 16g.

3,4-dibenzamido benzamide derivative, preparation method and application thereof

The invention discloses a 3,4-dibenzamido benzamide derivative (I), wherein R1, R2 and R3 are respectively and individually hydrogen, fluorine, chlorine, bromine, hydroxyl groups, alkoxy groups, amino groups or substituted amino groups. The alkoxy groups

AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R1, R2, R3 and R4 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.